These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 33593877)

  • 1. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
    Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
    Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Short NJ; Konopleva M; Kadia T; Kebriaei P; Daver N; Huang X; Masarova L; Cook R; Jain N; Jabbour E; Kantarjian H; Ravandi F
    Am J Hematol; 2021 Jul; 96(7):E229-E232. PubMed ID: 33780038
    [No Abstract]   [Full Text] [Related]  

  • 4. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
    Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
    Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
    Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
    Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
    Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
    Wang L; Lin N
    Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Murthy GSG; Saliba AN; Szabo A; Harrington A; Abedin S; Carlson K; Michaelis L; Runaas L; Baim A; Hinman A; Maldonado-Schmidt S; Venkatachalam A; Flatten KS; Peterson KL; Schneider PA; Litzow M; Kaufmann SH; Atallah E
    Haematologica; 2024 Sep; 109(9):2864-2872. PubMed ID: 38572562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
    Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
    Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
    Konopleva MY; Dail M; Daver NG; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Dunshee DR; Hamidi H; Ott MG; Hong WJ; Andreeff M
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):364-374. PubMed ID: 38378362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Canaani J; Frisch A; Pollyea DA; Schwartz M; Aumann S; Ganzel C; Haran A; Even-Zohar NG; Shaulov A; Vainstein V; Moshe Y; Ofran Y; Wolach O; Nachmias B
    Eur J Haematol; 2023 Sep; 111(3):365-372. PubMed ID: 37254665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.